BMYMP News and Press, Bristol-Myers Squibb $2Pr From 05/02/22

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2022 Q1 earnings call. For further details see: Bristol-Myers Squibb Company 2022 Q1 - Results - Earnings Call Presentation

Bristol-Myers Squibb Company (BMY) Q1 2022 Results Conference Call April 29, 2022 08:00 AM ET Company Participants Tim Power - VP & Head, IR Giovanni Caforio - Board Chair & CEO David Elkins - CFO Chris Boerner - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer an...

SPDV implements a dividend and free cash flow strategy in the S&P 500 Index. It follows an equal weight methodology in sectors and holdings. Valuation is attractive, but not quality and past performance. For further details see: SPDV: A Good Idea In Theory, But Reali...

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies withupcoming pay dates. For further details see: Dividend Champion, Contender, And...

Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 (MAESTRO-NASH) trial. Despite strong funda...

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD. RGX202 is the hidden asset, poised to make waves in the coming years. For further details see: Regenxbi...

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patient...

Historically, PPH generated a steady total return with a low yield up to 2 percent. PPH’s price multiples are considerably lower than its peers and index despite strong earnings and stable historical price growth. Half of PPH’s portfolio has been extremely productive...